Western blot analysis of extracts from HCT 116 cells, untreated (-) or treated with Doxorubicin #5927 (0.5 μM, 24 hr; +), either with or without KU-55933 pretreatment (10 μM, 1 hr; +), using Phospho-Chk2 (Thr68) (C13C1) Rabbit mAb #2197 (upper), Chk2 (D9C6) XP® Rabbit mAb #6334 (middle), and β-Actin (D6A8) Rabbit mAb #8457 (lower).
Chemical structure of KU-55933.
KU-55933 is supplied as a lyophilized powder. For a 10 mM stock, reconstitute 5 mg of powder in 1.26 ml of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
Molecular Weight: 395.5 g/mol
Molecular Formula: C21H17NO3S2
Solubility: Soluble in DMSO at 40 mg/ml or ethanol at 20 mg/ml.
KU-55933 is a potent and selective ATP-competitive inhibitor of ATM kinase (IC50 = 13 nM and Ki = 2.2 nM). This small molecule has been shown to sensitize cancer cells to ionizing radiation and chemotherapeutic agents (1). Treating senescent cancer cells (MCF7, A549, and HCT 116) with KU-55933 results in decreased viability and cell death (2). KU-55933 has neuroprotective capabilities by preventing damage caused by oxidative stress (3).
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
XP is a registered trademark of Cell Signaling Technology, Inc.